ClinicalTrials.gov
ClinicalTrials.gov Menu

ImmuniCell® in Patients With Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02459067
Recruitment Status : Terminated
First Posted : June 1, 2015
Last Update Posted : December 4, 2018
Sponsor:
Information provided by (Responsible Party):
TC Biopharm

Brief Summary:
To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC). The study is an adaptive design that has 3 stages: Stage 1 - dose escalation, Stage 2 - efficacy, and Stage 3 - confirm efficacy in one of the tumor types.

Condition or disease Intervention/treatment Phase
Malignant Melanoma Non-small Cell Lung Cancer Renal Cell Cancer Biological: ImmuniCell® Phase 2

Detailed Description:

This is an open-label trial of ImmuniCell® treatment of patients with malignant melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC) which are refractory to current treatment or who have indolent disease for which immunotherapy may be beneficial. The trial is designed to identify a safe dose of ImmuniCell® for future clinical trials, to identify a response signal from one or more of the cancers under investigation and to confirm the safety and efficacy in the selected target tumour.

The trial has three stages:

Stage I comprising a safety cohort of patients to identify a safe dose Stage II comprising an expanded patient group for response signal identification Stage III to confirm efficacy and safety.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
Study Start Date : December 2015
Actual Primary Completion Date : November 27, 2018
Actual Study Completion Date : November 27, 2018


Arm Intervention/treatment
Experimental: ImmuniCell®
Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
Biological: ImmuniCell®
Autologous γδ T Lymphocytes




Primary Outcome Measures :
  1. Proportion of patients with drug-related > grade 3 toxicity (except for nausea, vomiting or grade 3 diarrhoea without maximal supportive therapy; anaemia, alopecia, or asymptomatic grade 3 laboratory findings that last for < 7 days) [ Time Frame: 3 months ]
  2. Document the clinical response (immediate or delayed CR, PR, SD or PD) of the patients following ImmuniCell® treatment and assess the data for a response signal to guide the confirmatory stage [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Changes in markers of immune response (such as IFN-γ, IL-2 and TNF-α) before the first and subsequent ImmuniCell® infusions [ Time Frame: 12 months ]
    Changes in markers of immune response (such as IFN-γ, IL-2 and TNF-α) before the first and subsequent ImmuniCell® infusions

  2. Changes in peripheral T lymphocyte counts before the first and subsequent ImmuniCell® infusions (optional) [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients aged ≥18 years
  2. Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1
  3. Subjects with histological or cytological confirmation of advanced malignant melanoma, renal cell carcinoma or NSCLC which are refractory to current standard treatments or who have indolent disease for which immunotherapy may be beneficial
  4. Measurable disease according to the irRC criteria
  5. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted <2 weeks prior to Cycle 1:

    • Creatinine ≤ 1.5 x upper limit of normal (ULN) OR a calculated creatinine clearance ≥ 50 ml/min
    • Total bilirubin ≤ 1.5 x ULN
    • Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN with liver metastases
    • Absolute lymphocyte count ≥1.0 x 10E9/L
    • Absolute Neutrophil Count (ANC) ≥1.5 x 10E9/L
    • Platelets ≥100 x 10E9/L
    • Haemoglobin ≥ 10 g/dL
  6. Life expectancy of at least 3 months
  7. Suitable increase in starting γδ T cell number to final γδ T cell number in the proliferation assay between 10 days in culture
  8. Able to give informed, written consent
  9. For female patients and female partners of male patients: must be surgically sterile, postmenopausal, or compliant with two forms of contraception (one of which must be a barrier method) during and for 6 months after the treatment period; female patients must have a negative urine pregnancy test at screening and must not be breast-feeding.

Exclusion Criteria:

  1. Other primary cancers apart from non-melanoma skin cancers, carcinoma - in situ of the cervix, or a prior cancer treated with curative intent more than 2 years ago without any evidence or recurrent disease
  2. Uncontrolled systemic infection
  3. Systemic steroid therapy or other immune-suppressants (except in cases where the patient is receiving treatment with replacement doses for adrenal insufficiency)
  4. Treatment with bisphosphonates, for instance zoledronate, in the previous 3 months and throughout the trial
  5. New York Heart Association (NYHA) functional class ≥3 or myocardial infarction within 6 months
  6. Clinically-significant uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation not requiring therapy.
  7. Ulcerative Colitis / Inflammatory bowel disease, Addison's disease
  8. Pregnancy or lactation before or during the trial. A urine pregnancy test will be carried out at screening
  9. Taking any other investigational medicinal product (IMP) or participation in another interventional clinical trial in the previous 30 days
  10. Less than 4 weeks since systemic anti-cancer therapy (tyrosine kinase inhibitors, chemotherapy, immunotherapy, hormonal therapy, radiotherapy) and less than 6 weeks since mitomycin C and nitrosureas
  11. Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the trial or evaluation of the trial results
  12. Any other condition considered by a trial physician to be inappropriate for inclusion to the study such as contraindications to leukapheresis (contraindications to heparin which are: recent cerebral haemorrhage; peptic ulcer; recent surgery to eye or nervous system; hypersensitivity to heparin; past history of Type II heparin induced thrombocytopenia; past history of significant spontaneous haemorrhage; known haemophilia or other bleeding disorder).
  13. Serological evidence of active infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02459067


Locations
United Kingdom
Velindre Cancer Centre and University Hospital of Wales
Cardiff, United Kingdom
Western General Hospital
Edinburgh, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
St. James's University Hospital
Leeds, United Kingdom
University College London Hospital
London, United Kingdom
Churchill Hospital
Oxford, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Sponsors and Collaborators
TC Biopharm
Investigators
Principal Investigator: Jeff Evans, Prof. Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN

Responsible Party: TC Biopharm
ClinicalTrials.gov Identifier: NCT02459067     History of Changes
Other Study ID Numbers: TCB-101-001
First Posted: June 1, 2015    Key Record Dates
Last Update Posted: December 4, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Melanoma
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases
Urologic Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas